Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A structured narrative review synthesizing pathophysiological mechanisms, drug hepatotoxicity profiles, and a proposed clinical management framework for treatment-related liver injury in HBV-associated HCC, intended to guide clinical decision-making.
A narrative review synthesizing early clinical trial data on an emerging technology without meta-analysis, formal quality assessment, or definitive efficacy endpoints; represents current state of evidence rather than practice-changing guidance.
A narrative synthesis of epidemiological trends and clinical management implications for HCC in Europe, intended to inform practice and policy rather than report a primary research finding.
A narrative review synthesizing surveillance recommendations, implementation challenges, and emerging approaches across geographies, offering expert consensus on HCC screening practice rather than primary evidence of clinical efficacy.
A single case report of advanced HCC with rupture treated with combination immunotherapy and successfully transplanted; demonstrates feasibility but lacks comparator, control group, and generalizability needed to establish efficacy or change practice.
A multi-algorithm machine learning signature study with external validation across four datasets and functional validation of a candidate gene, showing clear prognostic separation but limited by retrospective cohort design and surrogate endpoints rather than prospective clinical outcomes.
This is a narrative review summarizing preclinical and in vitro organoid technologies without reporting original empirical data, clinical outcomes, or comparative efficacy in humans.
Single-centre retrospective study with modest sample size identifies ALBI score as prognostic for survival after TARE, but lacks prospective design, external validation, and mechanistic insight into clinical benefit.